Miura Global Management LLC Reduces Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Miura Global Management LLC trimmed its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 86.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 40,000 shares of the biotechnology company's stock after selling 260,000 shares during the period. ADMA Biologics comprises 0.9% of Miura Global Management LLC's portfolio, making the stock its 19th largest position. Miura Global Management LLC's holdings in ADMA Biologics were worth $800,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of ADMA. Price T Rowe Associates Inc. MD grew its holdings in ADMA Biologics by 13.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 60,924 shares of the biotechnology company's stock worth $403,000 after purchasing an additional 7,450 shares during the period. CWM LLC grew its holdings in ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company's stock worth $92,000 after purchasing an additional 4,367 shares during the period. SG Americas Securities LLC grew its holdings in ADMA Biologics by 3,084.6% in the second quarter. SG Americas Securities LLC now owns 363,742 shares of the biotechnology company's stock worth $4,067,000 after purchasing an additional 352,320 shares during the period. Roman Butler Fullerton & Co. purchased a new stake in ADMA Biologics in the second quarter worth about $378,000. Finally, Baader Bank Aktiengesellschaft purchased a new stake in ADMA Biologics in the second quarter worth about $514,000. 75.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ADMA. HC Wainwright increased their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a report on Friday, November 8th. Raymond James increased their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th.

Insider Buying and Selling

In related news, CFO Brad L. Tade sold 15,000 shares of the business's stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of the business's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now owns 153,941 shares of the company's stock, valued at approximately $2,843,290.27. This trade represents a 5.52 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is owned by corporate insiders.

ADMA Biologics Stock Performance

ADMA traded up $0.05 during trading on Wednesday, hitting $19.97. The company's stock had a trading volume of 1,184,723 shares, compared to its average volume of 3,617,746. The firm has a market cap of $4.72 billion, a PE ratio of 71.14 and a beta of 0.70. ADMA Biologics, Inc. has a one year low of $3.60 and a one year high of $23.64. The business's 50 day simple moving average is $19.08 and its 200-day simple moving average is $15.55. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $119.84 million during the quarter, compared to analysts' expectations of $107.25 million. During the same period last year, the company posted $0.01 earnings per share. As a group, sell-side analysts predict that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.